Minocycline Improves the Efficacy of EGFR Inhibitor Therapy: A Hypothesis

Ajit Venniyoor* and Bassim Al Bahrani

National Oncology Center, The Royal Hospital, Muscat, Oman

Skin rash is a side effect of drugs that inhibit epithelial growth factor receptor (EGFR) as a part of targeted therapy of cancer. Its appearance and severity correlates with survival. Minocycline, an oral tetracycline antibiotic, is recommended as treatment (and increasingly, for prevention) of the rash, though infection is seen in only one-third of the patients. Minocycline has additional anticancer properties such as poly(ADP-ribose) polymerase inhibition. It is proposed that such properties contribute to the efficacy of EGFR inhibitors and can also explain the positive correlation between grade of rash and survival as patients with higher grades of rash are more likely to receive minocycline. Early concurrent administration of minocycline is recommended in patients planned for EGFR therapy while awaiting trials proving this hypothesis.

Keywords: minocycline, EGFR inhibition, skin rash, PARP inhibitors, survival

Inhibition of epithelial growth factor receptor (EGFR) with either monoclonal antibodies (cetuximab, panitumumab) or tyrosine kinase inhibitors (erlotinib, gefitinib) is approved for the treatment of some subsets of cancers of colon, lung, pancreas, and head and neck. One of the major side effects of these drugs is an acne-form skin rash (1). Multiple trials have shown that the appearance and the degree of rash are associated with improved survival (2, 3). It is recommended that higher degrees of rash be treated with tetracyclines, such as minocycline (1), despite studies suggesting that only about 40% of them have an infection (4).

Minocycline, in addition to being an antibiotic, has multiple other actions (5). It is a poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor (6), and there is evidence that inhibition of PARP pathway could be useful in EGFR-dependent tumors. EGFR mutants have lower levels of BRCA1 expression (7) and have deficiencies in the homologous recombination repair pathways that make them sensitive to another PARP inhibitor, such as olaparib (8). In triple-negative breast cancer cell lines, a combination of EGFR and PARP inhibition have been shown to increase synthetic lethality (9). Synergy of EGFR and PARP inhibition has been reported on cell lines (10, 11), and data on combination of PARP inhibitors with anti-EGFR monoclonal antibodies has been reviewed (12). A trial is currently recruiting head and neck cancer patients in a Phase I trial for the combination of cetuximab and olaparib (NCT01758731) (13).

Interestingly, minocycline was chosen for the treatment of skin rash in the first randomized trial (conducted by Memorial Sloan Kettering Cancer Centre) for its anti-inflammatory rather than anti-infective effects (14).

Minocycline also appears to enhance the antitumor effects of 5-FU in tumor CT-26 xenograft mice (15). Therefore, it is possible that the increased activity of EGFR inhibitors and correlation with degree of skin rash can be attributed partly to concurrent use of minocycline.

Interestingly, the recently published Pan Canadian Rash trial (16) on the use of minocycline in the management of skin rash caused by erlotinib in lung cancer showed a trend toward
improved survival associated with the early use of minocycline (7.6 and 8 months in prophylactic and reactive use) versus if used only when severe rash appears (6 months). Thus, this hypothesis is worth exploring in prospective randomized trials. Analysis of existing data generated in Phase III trials using EGFR inhibitors with specific focus on survival versus minocycline use could also provide evidence supporting this hypothesis.

In the meantime, the use of minocycline should be recommended in patients on EGFR inhibitors even before the appearance of skin rash [in line with current recommendations (17)], for a possible survival effect. The antibiotic has been used over prolonged periods (3–4 months) for the treatment of acne vulgaris, with hyperpigmentation and a lupus-like syndrome as side effects (18). Repurposing of (benign) drugs for their anticancer effects is an active field of research, and minocycline appears to be an active drug for inclusion in this list (19).

**AUTHOR CONTRIBUTIONS**

Drs. AV and BB: conceived, wrote, and approved.

**FUNDING**

This article was published with an educational grant from Hoffman-La Roche.

**REFERENCES**

1. Burtness B, Anadkat M, Basti S, Hughes M, Lacouture ME, McClure JS, et al. NCCN task force report: management of dermatologic and other toxicities associated with PARP inhibition in patients with cancer. *J Natl Compr Canc Netw* (2009) 7(Suppl 1):S5–21.
2. Abdel-Rahman O, Fouad M. Correlation of cetuximab-induced skin rash and outcomes of solid tumor patients treated with cetuximab: a systematic review and meta-analysis. *Crit Rev Oncol Hematol* (2015) 93:127–35. doi:10.1016/j.critrevonc.2014.07.005
3. Liu HB, Wu Y, Lv TF, Yao YW, Yao YY, Yuan DM, et al. Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis. *PLoS One* (2013) 8:e55128. doi:10.1371/journal.pone.0055128
4. Eilers RE Jr, Gandhi M, Patel JD, Mulcahy ME, Agulnik M, Hensing T, et al. Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. *J Natl Cancer Inst* (2010) 102:47–53. doi:10.1093/jnci/djp439
5. Garrido-Mesa N, Zarzuelo A, Gálvez J. Minocycline: far beyond an antibiotic. *Br J Pharmacol* (2013) 169:337–52. doi:10.1111/bph.12139
6. Alano CC, Kauppinen TM, Valls AV, Swanson RA. Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations. *Proc Natl Acad Sci U S A* (2006) 103:9685–90. doi:10.1073/pnas.0600554103
7. Li H, Xie L, Lai BS. Association of EGFR mutations with low BRCA1 gene expression in non-small cell lung cancer. *Mol Clin Oncol* (2013) 1:195–9. doi:10.3892/mco.2012.34
8. Pfaffle HN, Wang M, Gheorghiu L, Ferraiolo N, Greninger P, Borgmann K, et al. EGFR-activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity. *Cancer Res* (2013) 73:6254–63. doi:10.1158/0008-5472.CAN-13-0044
9. Nowsheen S, Cooper T, Stanley JA, Yang ES. Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells. *PLoS One* (2012) 7:e46614. doi:10.1371/journal.pone.0046614
10. Sui H, Shi C, Yan Z, Li H. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy. *Drug Des Devel Ther* (2015) 9:3183–90. doi:10.2147/DDDT.S82035
11. Li N, Feng L, Liu H, Wang J, Kasembeli M, Tran MK, et al. PARP inhibition suppresses growth of EGFR-mutant cancers by targeting nuclear PKM2. *Cell Rep* (2016) S2211-1247:30359–X. doi:10.1016/j.celrep.2016.03.070
12. ClinicalTrials.gov. Study of Olaparib with Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer with Heavy Smoking History. (2016). Available from: https://clinicaltrials.gov/ct2/show/nct01758731
13. Yézamo J, Galindo M, Navarro J, Albanell J, Rovira A, Rojo F, et al. Enhancing tumor-targeting monoclonal antibodies therapy by PARP inhibitors. *Oncoimmunology* (2015) 5:e1065370. doi:10.1080/2162402X.2015.1065370
14. Scope A, Agero AL, Dusza SW, Mykowskii PL, Lieb JA, Saltz L, et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. *J Clin Oncol* (2007) 25:5390–6. doi:10.1200/JCO.2007.12.6987
15. Petrelli F, Borgonovo K, Cabiddu M, Lonati V, Barni S. Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials. *Lung Cancer* (2012) 78:8–15. doi:10.1016/j.lungcan.2012.06.009
16. Melosky B, Anderson H, Burke R, Chu Q, Hao D, Ho V, et al. The pan Canadian rash trial: a Phase III, randomized trial evaluating the impact of a possible survival effect in patients on EGFR-TKI induced skin toxicities in patients with metastatic lung cancer. *J Clin Oncol* (2016) 34:810–5. doi:10.1200/JCO.2015.62.3918
17. Petrelli F, Borgonovo K, Cabiddu M, Coinu A, Ghilardi M, Lonati V, et al. Antibiotic prophylaxis for skin toxicity induced by anti-EGFR agents: a systematic review and meta-analysis. *Br J Dermatol* (2016). doi:10.1111/bjd.14756
18. Ochsendorf E. Minocycline in acne vulgaris: benefits and risks. *Am J Clin Dermatol* (2010) 11:327–41. doi:10.2165/11319280-000000000-00000
19. Bertolini E, Suhkatme VP, Bouche G. Drug repurposing in oncology – patient and health systems opportunities. *Nat Rev Clin Oncol* (2015) 12:732–42. doi:10.1038/nrclinonc.2015.169

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2016 Venniyoor and Al Bahrani. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.